The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
Abstract
BACKGROUND & AIMS: We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD). METHODS: , 90% male) adults with NAFLD defined as liver fat fraction (LFF) > 5% on magnetic resonance imaging without other causes of hepatic steatosis were randomized to a supervised programme of energy restriction plus moderate-intensity exercise to induce ≥ 5% weight loss (DE group, n = 15), or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks, followed by 26 weeks with only advice to prevent weight regain. RESULTS: Diet and exercise and LI groups had significant (P < 0.01) and similar reductions in weight (-3.5 ± 3.3 vs -3.0 ± 2.2 kg), LFF (-8.1 ± 13.2 vs -7.0 ± 7.1%), serum alanine aminotransferase (-39 ± 35 vs -26 ± 33 U/L) and caspase-cleaved cytokeratin-18 (cCK-18) (-206 ± 252 vs -130 ± 158 U/L) at 26 weeks. At 52 weeks, the LI group significantly (P < 0.05) regained weight (1.8 ± 2.1 kg), LFF (4.0 ± 5.3%) and cCK-18 (72 ± 126 U/L), whereas these were unchanged in the DE group. CONCLUSIONS: Liraglutide was effective for decreasing weight, hepatic steatosis and hepatocellular apoptosis in obese adults with NAFLD, but benefits were not sustained after discontinuation, in contrast with lifestyle modification. Continuing the exercise learned in the structured programme contributed to the maintenance of liver fat reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immediately following treatment, and similar to our observations, the reductions in weight and liver fat content were similar”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [28]
In the citing paper
“Two published studies have used higher doses of liraglutide (3 mg) with a 26-week intervention period.”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [28]
In the citing paper
“there was increased weight regain in the liraglutide-treated group compared with the lifestyle intervention arm.28,29”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [28]
Citations
Cites
2011 Compendium of Physical Activities: A Second Update of Codes and MET Values
AINSWORTH, B. E., HASKELL, W. L., HERRMANN, S. D., MECKES, N., BASSETT, D. R., TUDOR-LOCKE, C., GREER, J. L., VEZINA, J., WHITT-GLOVER, M. C., & LEON, A. S. (2011) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31821ece12 · Cited by 6,317
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
DONNELLY, J. E., BLAIR, S. N., JAKICIC, J. M., MANORE, M. M., RANKIN, J. W., & SMITH, B. K. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181949333 · Cited by 2,658
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Szczepaniak, L. S., Nurenberg, P., Leonard, D. S., Browning, J. D., Reingold, J. S., Grundy, S. M., Hobbs, H. H., & Dobbins, R. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,573
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Regulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,159
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis
Feldstein, A. E., Wieckowska, A., López, R., Liu, Y., Zein, N. N., & McCullough, A. J. (2009) · Hepatology · doi:10.1002/hep.23050 · Cited by 728
Magnetic resonance elastography of liver: Technique, analysis, and clinical applications
Venkatesh, S. K., Yin, M., & Ehman, R. L. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23731 · Cited by 661
van der Poorten, D., Milner, K., Hui, J. M., Hodge, A. D., Trenell, M. I., Kench, J. G., London, R. M., Peduto, T., Chisholm, D. J., & George, J. (2008) · Hepatology · doi:10.1002/hep.22350 · Cited by 611
Thoma, C., Day, C. P., & Trenell, M. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.010 · Cited by 523
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review
Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., Takano, Y., Ueno, T., Koga, H., George, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.023 · Cited by 509
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Physiological adaptations to weight loss and factors favouring weight regain
Greenway, F. L. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.59 · Cited by 431
Kwok, R., Tse, Y. ‐., Wong, G. L. ‐., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L. ‐., & Wong, V. W. ‐. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12569 · Cited by 405
Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Wong, V. W., Chan, R., Wong, G. L., Cheung, B., Chu, C. W., Yeung, D. K., Chim, A. M., Lai, J. W.-Y., Li, L. S., Sea, M. M.-M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.013 · Cited by 346
Weight-loss intervention adherence and factors promoting adherence: a meta-analysis
Rogers, M., Lemstra, M., Bird, Y., Nwankwo, C., & Moraros, J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s103649 · Cited by 345
Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250
Therapies in non‐alcoholic steatohepatitis ( NASH )
Oseini, A. M., & Sanyal, A. J. (2017) · Liver International · doi:10.1111/liv.13302 · Cited by 244
Petit, J., Cercueil, J., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 238
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223
Houghton, D., Thoma, C., Hallsworth, K., Cassidy, S., Hardy, T., Burt, A. D., Tiniakos, D., Hollingsworth, K. G., Taylor, R., Day, C. P., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.031 · Cited by 209
Rifai, M. A., Silverman, M. G., Nasir, K., Budoff, M. J., Blankstein, R., Szklo, M., Katz, R., Blumenthal, R. S., & Blaha, M. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.011 · Cited by 208
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Shojaee-Moradie, F., Cuthbertson, D. J., Barrett, M., Jackson, N. C., Herring, R., Thomas, E. L., Bell, J., Kemp, G. J., Wright, J., & Umpleby, A. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2353 · Cited by 116
Buysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101
Khoo, J., Hsiang, J., Taneja, R., Law, N., & Ang, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13007 · Cited by 99
Self-citationHow Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?
Ghaemi, A., Taleban, F. A., Hekmatdoost, A., Rafiei, A., Hosseini, V., Amiri, Z., Homayounfar, R., & Fakheri, H. T. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.15227 · Cited by 80
Magnetic resonance elastography is as accurate as liver biopsy for liver fibrosis staging
Morisaka, H., Motosugi, U., Ichikawa, S., Nakazawa, T., Kondo, T., Funayama, S., Matsuda, M., Ichikawa, T., & Onishi, H. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25868 · Cited by 77
Washburn, R. A., Szabo, A. N., Lambourne, K., Willis, E. A., Ptomey, L. T., Honas, J. J., Herrmann, S. D., & Donnelly, J. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109849 · Cited by 74
Zhang, H., Pan, L., Ma, Z., Chen, Z., Huang, Z., Sun, Q., Lü, Y., Han, C., Lin, M., Li, X., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12809 · Cited by 63
Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease
Pelusi, S., & Valenti, L. V. C. (2018) · Liver International · doi:10.1111/liv.13972 · Cited by 59
Psychosocial predictors of weight regain in the weight loss maintenance trial
Brantley, P. J., Stewart, D. W., Myers, V. H., Matthews‐Ewald, M. R., Ard, J. D., Coughlin, J. W., Jerome, G. J., Samuel‐Hodge, C. D., Lien, L. F., Gullion, C. M., et al. (2014) · Journal of Behavioral Medicine · doi:10.1007/s10865-014-9565-6 · Cited by 54
Pugh, C. J. A., Sprung, V. S., Jones, H., Richardson, P., Shojaee‐Moradie, F., Umpleby, A. M., GREEN, D. J., Cable, N. T., Trenell, M. I., Kemp, G. J., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.123 · Cited by 52
Non‐pharmacological interventions in non‐alcoholic fatty liver disease patients
Ratziu, V. (2017) · Liver International · doi:10.1111/liv.13311 · Cited by 46
The preventive effect of sustained physical activity on incident nonalcoholic fatty liver disease
Kwak, M., Kim, D., Chung, G. E., Kim, W. K., & Kim, J. S. (2016) · Liver International · doi:10.1111/liv.13332 · Cited by 40
Lin, S. C., Heba, E. R., Bettencourt, R., Lin, G., Valasek, M. A., Lunde, O., Hamilton, G., Sirlin, C. B., & Loomba, R. S. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13951 · Cited by 26
Cited by
Sorted by citations
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299
Metadata
- Authors
- Khoo, J., Hsiang, J. C., Taneja, R., Koo, S., Soon, G., Kam, C. J., Law, N., & Ang, T.
- Affiliations
- Changi General Hospital (SG)
- Corresponding author
- Khoo, Joan
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2019-02-24
- Volume
- 39
- Issue
- 5
- Pages
- 941-949
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2913917435
- Cited by
- 136
- References
- 42
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 21 · 2023: 18 · 2022: 18 · 2021: 16 · 2020: 7 · 2019: 7
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Liver International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Medical Research Council (NMRC/CG/002/2013)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, non-alcoholic fatty liver disease, weight loss, lifestyle modification, caloric restriction, physical activity, GLP-1 receptor agonists, hepatic steatosis, liver fat fraction, hepatocyte apoptosis, caspase-cleaved cytokeratin 18, weight regain, obesity
- MeSH terms
- Liraglutide, Healthy Lifestyle, Adult, Female, Humans, Hypoglycemic Agents, Liver, Male, Middle Aged, Obesity, Prospective Studies, Singapore, Weight Loss, Exercise, Body Mass Index, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
